Physician profile
John Baird
NPI 1427493998
$84,477.22
in general payments reported to CMS, 2019-2025
13 companies · $36K in 2025
The $36K reported for 2025 was more than what 91% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.35 · 2020: $1,714 · 2022: $7,266 · 2023: $22K · 2024: $17K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $20K · Travel and Lodging: $7,973 · Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,640.00 |
| Consulting Fee | $19,660.00 |
| Travel and Lodging | $7,973.09 |
| Food and Beverage | $2,198.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $79,629.84 | 2019-2025 | Yescarta |
| Gilead Sciences, INC. | $2,060.00 | 2025 | |
| National Marrow Donor Program | $2,037.39 | 2025 | |
| Sobi, INC | $194.84 | 2024-2025 | |
| Genentech, INC. | $149.78 | 2022 | |
| Janssen Research & Development, LLC | $146.14 | 2025 | |
| Abbvie INC. | $129.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $33.62 | 2020 | |
| Merck Sharp & Dohme LLC | $24.90 | 2023 | |
| Genzyme Corporation | $24.80 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.97 | 2023 | Iclusig |
| Adc Therapeutics America, INC. | $22.67 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.